JADICELL - The Treatment That Could Crush Covid

Post Reply
curncman
Posts: 1125
Joined: Fri Jun 26, 2020 8:27 am

JADICELL - The Treatment That Could Crush Covid

Post by curncman »

The Treatment That Could Crush
Covid
Early trials show signaling cells eliminate the virus, calm the immune response and repairtissue damage.
By Kevin Kimberlin
Aug.13, 2020 718 pm ET
More than 500 clinical trials are under way world-wide in the race to find an effective
treatment for Covid-19. Everybody wants it; nobody has it—yet. But one of the most promising
therapies for Covid-19 patients uses “medicinal signaling cells,” or MSCs, which are found on
blood vessels throughout the body.
In preliminary studies, these cells cut the death rate significantly, particularly in the sickest
patients. With a powerful 1-2-3 punch, these cells eliminate the virus, calm the immune
overreaction known as a cytokine storm, and repair damaged lung tissue—a combination
offered by no other drug. This type of regenerative medicine could be as revolutionary as Jonas
Salk’s polio vaccine.
In one pilot study in March, doctors at Mount Sinai Hospital in New York treated a dozen
severely ill Covid-19 patients on ventilators with MSCs. Two infusions modulated their
hyperactive immune systems, and 83% of those patients survived. With such promising results,
the team at Mount Sinai and the supplier of the cells, Mesoblast Ltd. , won Food and Drug
Administration clearance and National Institutes of Health funding to conduct a randomized
trial on 300 patients. The first patients in the trial received the treatment in early May.
A July 10 article in the Lancet reported on 13 critically ill Covid-19 patients also treated with
MSCs. Eleven of the 13 patients lived—an 85% survival rate, which mirrors the results from
Mount Sinai. The number of virus-fighting T-cells rose even as inflammation fell, suggesting
that these cells can control the immune response as needed. In addition, chest X-rays showed
that the drug repaired lung tissue, in some cases within 48 hours.
Healing tissue is essential because the cytokine battle with the Covid-19 virus is so vicious that
it punches holes in the delicate lung membranes, allowing the virus to flood into the
bloodstream and body cavities. These holes must be repaired, as virus leaks create some of the
complications not usually associated with respiratory infections—blood clotting, heart attacks,
stroke and multiple organ failure, which cause about 40% of Covid-19-related deaths. Bloodvessel density, and thereby the number of MSCs, decreases as we age, gain weight or develop
diseases, which may explain why the elderly and those with chronic health conditions are
faring worst.
curncman
Posts: 1125
Joined: Fri Jun 26, 2020 8:27 am

Re: JADICELL - The Treatment That Could Crush Covid

Post by curncman »

Covid cases going up...much more hospitalizations......the country and the world needs cures.....
Vaccines will be spotty at best.....and do not guarantee that you will not get covid.....
CURES and medicines......... everything is pointing to stem cell as the future

We have one of the smartest and best stem cell therapy in JADICELL and STEMVACS ......the wait will be worth it for those of us who are in it to win it.
curncman
Posts: 1125
Joined: Fri Jun 26, 2020 8:27 am

Re: JADICELL - Celltrion's COVID-19 antibody drug cut recovery time-early study

Post by curncman »

Celltrion's COVID-19 antibody drug cut recovery time-early study

https://us.yahoo.com/news/celltrion-say ... 08464.html

Fri, November 6, 2020, 6:46 AM GMT+5:30
(Reuters) - South Korean drugmaker Celltrion Inc said on Friday patients treated with its experimental COVID-19 antibody drug in a small-size early-stage trial showed at least a 44% improvement in recovery time.

The result bodes well for Celltrion, which plans to seek conditional approval for the monoclonal antibody treatment, CT-P59, for emergency use by the end of this year in South Korea.

In its global Phase 1 trial that enrolled 18 patients with mild symptoms of COVID-19, 15 participants who received the treatment had a mean recovery time about 44% faster than three people in a placebo group.

No patients treated with CT-P59 in the study had so far required hospitalisation or other antiviral therapy as a result of COVID-19, and the treatment was well tolerated with no clinically significant safety issues, it said.

Celltrion, which is planning global Phase 2 and 3 trials of the drug, said last month it received regulatory approval for Phase 3 clinical trials from South Korea.

The third-stage trials will be conducted on about 1,000 asymptomatic coronavirus patients and those who have come into close contact with COVID-19 patients in Korea.

The treatment, the most advanced antibody drug in terms of research in South Korea, is directed against the surface of the coronavirus and designed to block it from locking on to human cells.

Celltrion began commercial production of the drug in September, which is likely to amount to around 1 million doses, in anticipation of demand in both domestic and overseas markets.

Monoclonal antibodies are manufactured copies of antibodies created by the body to fight an infection.

Developers of COVID-19 antibody treatments include U.S. firms Eli Lilly and Regeneron, Roche and Novartis.

No monoclonal antibody has been approved against COVID-19 so far.
Post Reply